Oaktree Specialty Lending reported adjusted net investment income of $29.6 million, or $0.34 per share, down from $32.2 million, or $0.37 per share in the prior quarter. Non-accruals fell to approximately 1.8% of the total debt portfolio at fair value, with dollar amounts down from $81 million a year ago to $45 million. The company priced $300 million of five-year unsecured notes due 2031 with a 7% coupon.
OCSL · Oaktree Specialty Lending Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 47%
- Last earnings
- Nov 17, 2026
- Latest filing
- 10-K · Nov 17
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Oaktree Specialty Lending's fourth-quarter net investment income fell to $0.34 per share from $0.37, and NAV per share dropped to $15.63. It declared a $0.30 quarterly distribution plus a $0.02 supplemental distribution, payable December 31, 2026.
Oaktree Specialty Lending reports investments at fair value of $2,706.4 million at September 30, 2026, down from $2,847.8 million, primarily from repayments and net realized and unrealized losses.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q4 FY26 earnings call · Nov 17, 2026TL;DR. Non-accruals fell 44% year over year, and the September notes drew strong demand while floating-rate exposure should help net investment income after the rate hike. Adjusted net investment income fell both quarterly and for the full year, Pluralsight was added to non-accrual, and the quarter carried $7.0 million of realized and unrealized losses.
- + Non-accruals at fair value fell 44%, from $81 million a year ago to $45 million. new
- + September $300 million unsecured notes priced with strong demand and a final order book more than three times the deal size. new
- + Floating-rate exposure means the September rate hike is expected to lift net investment income, with the net impact positive. new
- + FDA approval for BioExcel's drug triggered the full $67.5 million additional milestone to the lenders. new
- + Moody's revised the ratings outlook to stable and kept the BAA3 rating unchanged. new
- − Adjusted net investment income fell to $29.6 million, or $0.34 per share, from $32.2 million, or $0.37 per share, in the prior quarter.
- − Full-year adjusted net investment income fell to $131.7 million, or $1.49 per share, from $151.3 million, or $1.76 per share.
- − Pluralsight's first-out term loan was added to non-accrual as the company continues to underperform. new
- − Adjusted total investment income decreased $1.1 million in the quarter, driven by a lower average portfolio balance. new
- − The quarter had adjusted net realized and unrealized losses of $7.0 million on certain debt and equity investments.
- − BioXL Therapeutics was added to non-accrual this quarter as a new borrower. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings (loss) non-GAAP | $39.52M | year ended September 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net increase (decrease) in net assets resulting from operations 40.29M
-1.74M Interest income amortization (accretion) related to merger accounting adjustments
+977K Net realized and unrealized gains (losses) related to merger accounting adjustments
= Adjusted earnings (loss) 39.52M
|
|||
| Adjusted earnings (loss) per share non-GAAP | $0.26 | three months ended September 30, 2026 | — |
|
|
|||
| Adjusted Liquidity | $815M | 9/30/2026 | — |
| Adjusted net investment income non-GAAP | $131.7M | the full year ended September 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP net investment income 133.41M
-1.74M Interest income amortization (accretion) related to merger accounting adjustments
+0K Part II incentive fee
= Adjusted net investment income 131.66M
|
|||
| Adjusted net investment income per share non-GAAP | $0.34 | the quarter ended September 30, 2026 | — |
|
|
|||
| Adjusted net realized and unrealized gains (losses), net of taxes non-GAAP | -92.14M | year ended September 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP net realized and unrealized gains (losses), net of taxes -93.12M
+977K Net realized and unrealized gains (losses) related to merger accounting adjustments
= Adjusted net realized and unrealized gains (losses), net of taxes -92.14M
|
|||
| Adjusted net realized and unrealized gains (losses), net of taxes per share non-GAAP | -$0.08 | quarter ended September 30, 2026 | — |
|
|
|||
| Adjusted total investment income non-GAAP | $281.4M | the year ended September 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP total investment income 283.13M
-1.74M Interest income amortization (accretion) related to merger accounting adjustments
= Adjusted total investment income 281.38M
|
|||
| Adjusted total investment income per share non-GAAP | $0.77 | three months ended 9/30/2026 | — |
|
|
|||
| Asset coverage ratio at end of period (5) | 195% | Year ended September 30, 2026 filing | — |
|
|
|||
| Average debt per share (1) | $17.27 | Year ended September 30, 2026 filing | — |
|
|
|||
| Average portfolio company debt size | 16.79M | as of September 30, 2026 | — |
| Cash component of weighted average yield on debt investments | 8.4% | as of September 30, 2026 | — |
|
|
|||
| Common shares outstanding at end of period | 88.09M | Year ended September 30, 2026 filing | — |
| Coupon interest rate (net of effect of interest rate swaps) - 2027 Notes | 5.69% | the year ended September 30, 2026 filing | — |
| Coupon interest rate (net of effect of interest rate swaps) - 2029 Notes | 6.91% | the year ended September 30, 2026 filing | — |
| Coupon interest rate (net of effect of interest rate swaps) - 2030 Notes | 5.98% | the year ended September 30, 2026 filing | — |
| Coupon interest rate (net of effect of interest rate swaps) - 2031 Notes | 6.53% | the year ended September 30, 2026 filing | — |
| Credit Facilities Committed | $1.16B | 9/30/2026 | — |
| Credit Facilities Drawn | -$166M | 9/30/2026 | — |
| Funded investments | $910.3M | the year ended September 30, 2026 filing | — |
| Investment commitments originated | $905.6M | the year ended September 30, 2026 filing | — |
| Liquidity | $1.04B | As of 9/30/2026 | — |
| Net asset value ("NAV") per share | $15.63 | as of September 30, 2026 | — |
| Net asset value at end of period | $21.84 | Year ended September 30, 2021 filing | — |
| Net asset value per common share | $15.63 | fiscal 2026 filing | — |
| Net asset value per share | $15.63 | quarter ended September 30, 2026 | — |
|
|
|||
| Net asset value per share at end of period | $15.63 | Year ended September 30, 2026 filing | — |
| Net Assets | $1.38B | 9/30/2026 | — |
| New funded investment activity | $162,400 | three months ended September 30, 2026 | — |
| Non-accrual investments as a percentage of debt investments at cost | 4% | as of September 30, 2026 | — |
| Non-accrual investments as a percentage of debt investments at fair value | 1.8% | as of September 30, 2026 | — |
| Non-accrual investments at fair value | 45.03M | as of September 30, 2026 | — |
| Number of investments on non-accrual | 6 | three months ended September 30, 2026 | — |
| Number of new investment commitments in new portfolio companies | 12 | three months ended September 30, 2026 | — |
| Number of portfolio companies | 170 | as of September 30, 2026 | — |
| Number of portfolio company exits | 31 | the year ended September 30, 2026 filing | — |
| Percentage fixed-rate | 9% | three months ended September 30, 2026 | — |
| Percentage floating-rate | 91% | as of September 30, 2026 | — |
| PIK interest | 6.4% | the year ended September 30, 2026 filing | — |
| PIK interest as a percentage of interest income | 6.4% | the year ended September 30, 2026 filing | +1.6% |
|
|
|||
| Pro Forma Adjusted Liquidity | $465M | 9/30/2026 | — |
| Proceeds from prepayments, exits, other paydowns and sales | $973.2M | the year ended September 30, 2026 filing | — |
| Ratio of net expenses to average net assets (3) | 10.53% | Year ended September 30, 2026 filing | — |
|
|
|||
| Ratio of net investment income to average net assets (3) | 9.42% | Year ended September 30, 2026 filing | — |
|
|
|||
| Ratio of portfolio turnover to average investments at fair value | 32.37% | Year ended September 30, 2026 filing | — |
|
|
|||
| Ratio of total expenses to average net assets (3) | 10.53% | Year ended September 30, 2026 filing | — |
|
|
|||
| Total debt outstanding | $1.42B | as of September 30, 2026 | — |
| Total for the year ended September 30, 2026 (amount per share) | $1.47 | fiscal 2026 filing | — |
| Total quarterly distributions per share | $0.32 | quarter ended September 30, 2026 | — |
| Total return | 2.76% | Year ended September 30, 2026 filing | — |
|
|
|||
| Total return (2) | 2.76% | Year ended September 30, 2026 filing | — |
| Undrawn capacity under credit facility | $994M | as of September 30, 2026 | — |
| Unfunded Commitments | -$226M | 9/30/2026 | — |
| Unfunded investment commitments | $252.6M | as of September 30, 2026 | — |
| Unrestricted cash and cash equivalents | $45.1M | as of September 30, 2026 | — |
| Weighted average interest rate on debt outstanding | 6.2% | quarter ended September 30, 2026 | — |
| Weighted average interest rate on Syndicated Facility borrowings | 5.73% | year ended September 30, 2026 filing | — |
| Weighted average yield on debt investments | 9.4% | as of September 30, 2026 | — |
|
|
|||
| Weighted average yield on new debt investment commitments | 9.6% | the fourth quarter (4Q 2026) | — |
| Weighted average yield on new debt investments | 9.6% | the quarter ended September 30, 2026 | — |
|
|
|||
| Weighted average yield on total portfolio investments | 9.1% | as of September 30, 2026 | — |
|
|
|||
| Adjusted net realized and unrealized losses, net of taxes non-GAAP | $2.1M | Q3 FY2026 | — |
| New investment commitments | $206.4M | Q3 FY2026 | — |
| Weighted average outstanding debt | $1.5B | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCSL
this stock
Oaktree Specialty Lending Corp
|
$1.03B | -8.0% | — | 25.5 | 3.6% |
|
BLK
BlackRock, Inc.
|
$178.51B | +2.9% | +16.2% | 25.1 | 1.3% |
|
BN
BROOKFIELD Corp
|
$84.03B | -17.7% | — | — | 1.0% |
|
BX
Blackstone Inc.
|
$83.22B | -28.1% | +9.2% | 24.7 | 2.6% |
|
KKR
KKR & Co. Inc.
|
$78.99B | -30.5% | -11.0% | — | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 16
Oaktree Specialty Lending's fourth-quarter net investment income fell to $0.34 per share from $0.37, and NAV per share dropped to $15.63. It declared a $0.30 quarterly distribution plus a $0.02 supplemental distribution, payable December 31, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCSL | -3.6% | +2.5% | -3.7% | -3.5% | -8.0% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +4.9% | +11.7% | +5.5% | +5.3% | -9.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.